What peri‑operative hormone replacement regimen (glucocorticoid and thyroid hormone) is recommended for a 32‑year‑old female with a sellar mass and hemorrhagic infarction presenting with visual disturbance, headache, photophobia, meningismus, peripheral edema, muscle aches, fatigue, depressed mood, dizziness, and recent weight gain?

Recommended Perioperative Hormone Replacement Regimen

For this 32-year-old female with pituitary apoplexy (hemorrhagic sellar mass), the correct perioperative regimen is hydrocortisone and levothyroxine (Option 4).

Clinical Reasoning

This patient presents with classic pituitary apoplexy—a hemorrhagic infarction of a sellar mass causing acute secondary adrenal insufficiency and likely central hypothyroidism. Her symptoms (visual disturbance, headache, photophobia, meningismus, fatigue, weight gain, depressed mood) are consistent with both the mass effect and hypopituitarism.

Glucocorticoid Management

Hydrocortisone is the glucocorticoid of choice perioperatively, not dexamethasone as the primary agent. According to UK guidelines for adrenal insufficiency management during surgery 1:

• Intraoperatively: Hydrocortisone 100 mg IV at induction, followed immediately by continuous infusion of 200 mg/24 hours
• Postoperatively: Continue hydrocortisone 200 mg/24 hours IV infusion while NPO (alternatively, 50 mg every 6 hours IM)
• Once stable: Resume enteral dosing at double the replacement dose for 48 hours, or up to a week following major surgery

The guidelines do mention dexamethasone 6-8 mg IV as an alternative that suffices for 24 hours 1, but this is listed as a secondary option for patients already on chronic steroids, not as the primary recommendation for acute adrenal insufficiency in pituitary apoplexy.

Thyroid Hormone Replacement

Levothyroxine must be included because central hypothyroidism is highly likely given the pituitary mass with hemorrhage 2. However, there is a critical safety consideration:

• Thyroid hormone should only be initiated AFTER glucocorticoid replacement is established 2
• Starting levothyroxine before cortisol replacement can precipitate adrenal crisis by increasing cortisol metabolism
• The Endocrine Society guidelines explicitly recommend using L-T4 therapy before nonemergency surgery and throughout the perioperative period in patients with preoperative central hypothyroidism 2

Why Other Options Are Incorrect

Option 1 (hydrocortisone, ethinyl estradiol, levothyroxine): Ethinyl estradiol is not indicated perioperatively. While this 32-year-old woman may have central hypogonadism, sex steroid replacement is not a perioperative priority and should be addressed after acute stabilization.

Option 2 (Dexamethasone, decompression, levothyroxine): While dexamethasone can be used, it's not the first-line glucocorticoid for perioperative coverage in adrenal insufficiency. Hydrocortisone is preferred because it provides both glucocorticoid and mineralocorticoid activity at high doses and allows for more physiologic dosing adjustments 1.

Option 3 (fludrocortisone and levothyroxine): This omits glucocorticoid replacement entirely. Fludrocortisone provides only mineralocorticoid activity and is not needed in secondary adrenal insufficiency because the renin-angiotensin-aldosterone system remains intact (aldosterone deficiency occurs only in primary adrenal insufficiency) 1. The high-dose hydrocortisone used perioperatively provides sufficient mineralocorticoid effect.

Key Clinical Pitfalls

1. Never start levothyroxine before glucocorticoid replacement—this can precipitate life-threatening adrenal crisis
2. Do not use fludrocortisone in secondary adrenal insufficiency—mineralocorticoid production is preserved
3. Ensure adequate stress-dose steroids perioperatively—the standard 100 mg hydrocortisone bolus followed by 200 mg/24h infusion matches the physiologic stress response 1
4. Monitor for diabetes insipidus postoperatively—common after pituitary surgery and requires separate management with desmopressin if it develops 2

Postoperative Considerations

After surgery, this patient will need:

• Reassessment of all pituitary axes starting at 6 weeks postoperatively 2
• Gradual taper of hydrocortisone to maintenance dosing (typically 15-25 mg daily in divided doses)
• Adjustment of levothyroxine based on free T4 levels (not TSH, which will be unreliable with pituitary dysfunction)
• Long-term follow-up, as recent case reports demonstrate that both surgical and conservative management may require subsequent intervention for tumor regrowth 3, 4